Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe

NCT ID: NCT03388398

Last Updated: 2023-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30642 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the impact of Zimbabwe's program for the prevention of mother-to-child HIV transmission (PMTCT) on vertical transmission of HIV infection and HIV-free survival among infants exposed to HIV. The study will test the hypothesis that the accelerated PMTCT program in Zimbabwe will result in fewer new HIV infections in infants and will increase infant survival.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The World Health Organization (WHO) recommends that all pregnant women receive antiretroviral therapy (ART) during pregnancy and breastfeeding ("Option B") or ideally throughout their lives regardless of clinical stage ("Option B+"). In February 2013, Zimbabwe's Ministry of Health and Child Welfare (MoHCW) declared that Zimbabwe would begin implementing Option B+ in October of 2013. This impact evaluation utilizes serial population-based, community-level surveys to comprehensively assess the prevention of mother-to-child HIV transmission strategy (PMTCT) 'Option B+' among mother-infant pairs in Zimbabwe. The investigators will assess the population-level impact of Option B+ in Zimbabwe using serial community-based cross-sectional serosurveys with data from three time points: 2012 (pre-Option A standard of care), 2014 (post-Option A / pre-Option B+), and 2017 (post Option B+ implementation) in order to monitor population-level trends in MTCT and HIV-free infant survival.

The investigators will compare outcomes among infants from 2017 to outcomes among mother-infant pairs who participated in similar surveys conducted in 2012 and 2014. These community-level data, along with in-depth facility survey data, will also allow the investigators to examine impact heterogeneity by the extent of integration of PMTCT and ART services at the facility. Together with effectiveness data from the serosurveys, facility-level resource utilization and cost data will allow assessment of Option B+ cost-effectiveness. In addition, this study will also include a population-based, community-level survey conducted in 2017 to assess retention of mothers in ART services after weaning (19-36 months postpartum). These data will allow the investigators to assess HIV-infected mothers' retention in care at the time of the survey, when most mothers will have stopped breastfeeding

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mother-Infant Pairs

Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.

No interventions assigned to this group

Mothers or caregivers

Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.

No interventions assigned to this group

Healthcare staff

Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.

No interventions assigned to this group

Providers

Health care providers (at least 18 years of age) at select participating healthcare facilities.

No interventions assigned to this group

Patients

Patients (at least 18 years of age) receiving care at select participating healthcare facilities.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mother or caregiver is 16 years of age or older
* Delivered or provides care for an infant (alive or deceased) who is or who would have been 9-18 months of age at the time of the survey
* Able and willing to provide written informed consent


* At least 16 years of age or older
* Delivered an infant (alive or deceased) who is or who would have been 19-36 months of age at the time of the survey
* Able and willing to provide written informed consent


* At least 18 years of age or older
* Currently providing PMTCT services at one of the 157 selected facilities
* Able and willing to provide written informed consent


* At least 18 years of age or older
* Currently providing ANC or ART care directly to clients at one of the 20 purposefully selected facilities
* Splitting time as a provider between one or more of the following HIV services: HIV testing and counseling (HTC), prevention of mother-to-child transmission (PMTCT), and male circumcision (MC)
* Able and willing to provide written informed consent


* At least 18 years of age or older
* Received HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), or male circumcision (MC) services at one of the 20 purposefully selected facilities on the day of the interview
* Able and willing to provide verbal consent

Exclusion Criteria

* Mother or caregiver is younger than 16 years of age
* Infant (alive or deceased) is not/would not have been 9-18 months of age at the time of the survey


* Mother or caregiver is younger than 16 years of age
* Infant (alive or deceased) is not/would not have been 19-36 months of age at the time of the survey


* Health care staff is younger than 18 years of age
* Health care staff is not currently providing PMTCT services at one of the 157 selected facilities


* Provider is younger than 18 years of age
* Currently not providing ART care directly to clients at one of the 20 purposefully selected facilities
* Does not split time as a provider between one or more of the following HIV services: HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), and male circumcision (MC)


* Patient is younger than 18 years of age
* Did not receive HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), or male circumcision (MC) services at one of the 20 purposefully selected facilities on day of interview
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre for Sexual Health and HIV/AIDS Research Zimbabwe (CeSHHAR Zimbabwe)

OTHER

Sponsor Role collaborator

Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).

OTHER

Sponsor Role collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

Liverpool School of Tropical Medicine

OTHER

Sponsor Role collaborator

Ministry of Health and Child Welfare, Zimbabwe

OTHER

Sponsor Role collaborator

Elizabeth Glaser Pediatric AIDS Foundation

OTHER

Sponsor Role collaborator

Children's Investment Fund Foundation

OTHER

Sponsor Role collaborator

University of California, Berkeley

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frances Cowan, MSc, MD

Role: PRINCIPAL_INVESTIGATOR

Liverpool School of Tropical Medicine, The Centre for Sexual Health and HIV/AIDS Research Zimbabwe

Nancy Padian, MPH, Ph.D

Role: PRINCIPAL_INVESTIGATOR

University of California, Berkeley

References

Explore related publications, articles, or registry entries linked to this study.

Koyuncu A, Dufour MK, McCoy SI, Bautista-Arredondo S, Buzdugan R, Watadzaushe C, Dirawo J, Mushavi A, Mahomva A, Cowan F, Padian N. Protocol for the evaluation of the population-level impact of Zimbabwe's prevention of mother-to-child HIV transmission program option B+: a community based serial cross-sectional study. BMC Pregnancy Childbirth. 2019 Jan 8;19(1):15. doi: 10.1186/s12884-018-2146-x.

Reference Type DERIVED
PMID: 30621615 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01HD080492-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R01HD080492-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.